-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Oscar Health to Sell, Lowers Price Target to $11

Benzinga·07/15/2025 12:31:01
Listen to the news
UBS analyst Jonathan Yong downgrades Oscar Health (NYSE:OSCR) from Neutral to Sell and lowers the price target from $15 to $11.